| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC2435 |
| Trial ID | NCT04526509 |
| Disease | Lung Non-Small Cell Carcinoma | Synovial Sarcoma | Myxoid Liposarcoma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | GSK3901961 |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors |
| Year | 2020 |
| Country | United States |
| Company sponsor | GlaxoSmithKline |
| Other ID(s) | 209012|2019-004446-14 |
| Cohort1: GSK3901961_NSCLC | |||||||||
|
|||||||||
| Cohort2: GSK3901961_SS/MRCLS | |||||||||
|
|||||||||
| Cohort3: GSK3845097_SS/MRCLS | |||||||||
|
|||||||||
| Cohort4: GSK4427296_SS/MRCLS | |||||||||
|
|||||||||